Patents Assigned to Dana-Farber Cancer Institute, Inc.
  • Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy
    Patent number: 11505831
    Abstract: The present invention relates to gene expression signatures that predict response and resistance to targeted therapy and immunotherapy.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 22, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Xiaole Liu, Peng Jiang
  • COMPOSITIONS AND METHODS FOR TREATMENT OF A POOR PROGNOSIS SUBTYPE OF COLORECTAL CANCER
    Publication number: 20220364184
    Abstract: The present invention relates to compositions and methods for diagnosing and treating colorectal cancer.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ruben D. Carrasco, Meng Jiang, Tomasz Sewastianik
  • METHODS OF HIGH-THROUGHPUT IDENTIFICATION OF T CELL EPITOPES BY CAPTURING CYTOKINES ON THE SURFACE OF ANTIGEN-PRESENTING CELLS
    Publication number: 20220364079
    Abstract: The present invention relates to a methods for high throughput screening of epitopes that are involved in T cell activation.
    Type: Application
    Filed: September 23, 2020
    Publication date: November 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Matthew Meyerson, Mark N. Lee
  • METHODS AND COMPOSITIONS FOR THE POSITIVE SELECTION OF PROTEIN DESTABILIZERS
    Publication number: 20220357311
    Abstract: The present application relates, in some aspects, to the development of an assay that uses cell survival and/or cell viability as a phenotypic identifier to positively select for agents that destabilize a protein of interest.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 10, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: William G. Kaelin, Vidyasagar Koduri
  • Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof
    Patent number: 11492403
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 8, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • Compositions and methods for targeting cancer-specific sequence variations
    Patent number: 11492670
    Abstract: The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or a sequence otherwise specific for a cancer cell compared to a non-cancer cell. The invention further relates to methods for treating cancer, comprising administering such sequence-specific DNA targeting agents. The invention further relates to methods for preparing sequence-specific DNA targeting agent, as well as screening methods using the DNA targeting agents.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 8, 2022
    Assignees: THE BROAD INSTITUTE INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.
    Inventors: William C. Hahn, Andrew Aguirre, April Cook, Glenn Cowley, Robin Meyers, David E. Root, Aviad Tsherniak, Barbara Weir, Francisca Vazquez
  • KDM INHIBITORS AND USES THEREOF
    Publication number: 20220348563
    Abstract: Provided herein are compounds that inhibit histone lysine demethylase (KDM) and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and methods of treating or preventing diseases (e.g., proliferative diseases, e.g., cancer). In certain embodiments, the compounds described herein are represented by formulas (I) and (II).
    Type: Application
    Filed: September 10, 2020
    Publication date: November 3, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Paul M. Park, Chengkui Pei, Xiaofeng Zhang
  • MICROGLIA SPECIFIC PROMOTERS AND METHODS OF USE THEREFORE
    Publication number: 20220348962
    Abstract: The present disclosure features methods and compositions for expressing transgenes in microglia. The disclosed compositions comprise isolated fragments of human and murine translocator protein (TSPO) promoters and expression cassettes comprising the same. The methods involve using these promoters and/or expression cassettes to express transgenes in a cell.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 3, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Valentina POLETTI, Marco PEVIANI, Francisco J. MOLINA-ESTEVEZ
  • Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
    Patent number: 11485787
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: November 1, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • RAPID PREDICTION OF DRUG RESPONSIVENESS
    Publication number: 20220340976
    Abstract: The present disclosure relates to compositions and methods for rapid prediction, based upon early single cell transcriptomic assessment of a biopsied sample obtained from a subject, of whether a subject will be responsive to a drug.
    Type: Application
    Filed: September 1, 2020
    Publication date: October 27, 2022
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Andrew J. Aguirre, Francisca Vazquez, Aviad Tsherniak, James McFarland, Brenton Paolella
  • Methods for genome characterization
    Patent number: 11479878
    Abstract: The invention provides methods of using low coverage sequencing to assess the relative fraction of tumor versus normal DNA in a sample, and to assess copy number alterations present in the sample.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 25, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gavin Ha, Viktor Adalsteinsson, Samuel Freeman
  • CRISPR EFFECTOR SYSTEM BASED MULTIPLEX CANCER DIAGNOSTICS
    Publication number: 20220333208
    Abstract: Systems and methods for rapid diagnostics related to the use of CRISPR effector systems and optimized guide sequences, including multiplex lateral flow diagnostic devices and methods of use, including for detection of cancer markers, are provided.
    Type: Application
    Filed: September 3, 2020
    Publication date: October 20, 2022
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jonathan Gootenberg, Omar Abudayyeh, Jeremy Koob, Rahul Vedula, Coleman Lindsley, Feng Zhang
  • METHODS AND COMPOSITIONS FOR RECONSTITUTING MICROGLIA
    Publication number: 20220323503
    Abstract: The present disclosure features CX3CR1 hemizygous and/or homozygous defective cells and methods of using such cells for the treatment of a metabolic or neurological disorder. The disclosed methods include methods for making and modifying CX3CR1 hemizygous and/or homozygous defective cells, such as hematopoietic stem progenitor cells. Other disclosed methods include methods of treating a subject having or suspected of having a metabolic or neurological disease comprising administering to the subject a composition comprising a hemizygous and/or homozygous defective CX3CR1 cell. The CX3CR1 hemizygous and/or homozygous defective cell may be modified to have a nucleic acid molecule encoding a therapeutic polypeptide or polynucleotide.
    Type: Application
    Filed: August 6, 2020
    Publication date: October 13, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Annita MONTEPELOSO
  • USP7 inhibitors for treating multiple myeloma
    Patent number: 11465983
    Abstract: The present disclosure relates to inhibitors of USP7 useful in the treatment of cancers, and other USP7 mediated diseases, having the Formula: wherein R1, R2, R3, R4, R5, R6, and n are described herein.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: October 11, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Sara Buhrlage, Kenneth C. Anderson, Dharminder Chauhan, Sirano Dhe-Paganon, Xiaoxi Liu, Hyuk-Soo Seo
  • Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
    Patent number: 11466064
    Abstract: Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 11, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Rosalind Segal, Loren D. Walensky, Lisa Vaughn Goodrich, Sarah Elizabeth Raissi, Maria F. Murphy, Gregory H. Bird
  • Monoclonal antibodies that bind human CD161
    Patent number: 11459389
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: October 4, 2022
    Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Karl Dane Wittrup, Kai Wucherpfennig, Byong Ha Kang, Nathan D. Mathewson
  • USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING
    Publication number: 20220305048
    Abstract: Disclosed herein are methods for treating a subject having cancer by coadministering a stimulator of interferon signaling and a heparin polysaccharide. Also disclosed herein are pharmaceutical compositions that include a stimulator of interferon signaling and a heparin polysaccharide.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 29, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Shriram Sundararaman, Erik Knelson, Shunsuke Kitajima, David Barbie, Saemi Han
  • USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS
    Publication number: 20220305016
    Abstract: The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).
    Type: Application
    Filed: January 21, 2022
    Publication date: September 29, 2022
    Applicants: The General Hospital Corporation, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Marc Wein, Henry Kronenberg, Thomas Sundberg, Ramnik Xavier, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Alykhan Shamji
  • DNA NANOSTRUCTURE-BASED VACCINES
    Publication number: 20220305119
    Abstract: Provided herein, in some embodiments, are nucleic acid nanostructure-based vaccines.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 29, 2022
    Applicants: Dana-Farber Cancer Institute, Inc., Korea Institute of Science and Technology
    Inventors: William M. Shih, Ju Hee Ryu, Yang Zeng
  • Combination therapy with neoantigen vaccine
    Patent number: 11452768
    Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 27, 2022
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine J. Wu, Edward F. Fritsch